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Background: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide, with a prevalence
of approximately 100 million patients. There is evidence that antiplatelet agents and antihypertensive medications could reduce
the risk of new vascular events in this population; however, treatment adherence is very low. An SMS text messaging intervention
was recently developed based on behavior change techniques to increase adherence to pharmacological treatment among patients
with a history of ASCVD.
Objective: This study aims to evaluate the efficacy and safety of an SMS text messaging intervention to improve adherence to
cardiovascular medications in patients with ASCVD.
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Methods: A randomized controlled clinical trial for patients with a prior diagnosis of cardiovascular events, such as acute
myocardial infarction, unstable angina, cerebrovascular disease, or peripheral artery disease, in one center in Colombia was
conducted. Patients randomized to the intervention arm were assigned to receive SMS text messages daily for the first 4 weeks,
5 SMS text messages on week 5, 3 SMS text messages each in weeks 6 and 7, and 1 SMS text message weekly from week 8 until
week 52. In contrast, patients in the control arm received a monthly SMS text message reminding them of the next study appointment
and the importance of the study, requesting information about changes in their phone number, and thanking them for participating
in the study. The primary endpoint was the change in low-density lipoprotein cholesterol (LDL-C) levels, whereas the secondary
endpoints were the changes in thromboxane B2 levels, heart rate, systolic and diastolic blood pressure, medication adherence,
cardiac and noncardiac mortality, and hospitalization. Linear regression analyses and bivariate tests were performed.
Results: Of the 930 randomized patients, 805 (86.5%) completed follow-up and were analyzed for the primary endpoint. There
was no evidence that the intervention changed the primary outcome (LDL-C levels; P=.41) or any of the secondary outcomes
evaluated (all P>.05). There was also no evidence that the intervention was associated with adverse events.
Conclusions: In this study, there was no evidence that a behavior modification intervention delivered by SMS text messaging
improved LDL-C levels, blood pressure levels, or adherence at 12 months. More research is needed to evaluate whether different
SMS text messaging strategies, including personalized messages and different timings, are effective; future studies should include
mixed methods to better understand why, for whom, and in which context (eg, health system or social environment) SMS text
messaging interventions work (or not) to improve adherence in patients with ASCVD.
Trial Registration: ClinicalTrials.gov NCT03098186; https://clinicaltrials.gov/ct2/show/NCT03098186
International Registered Report Identifier (IRRID): RR2-10.1136/bmjopen-2018-028017
(JMIR Mhealth Uhealth 2021;9(7):e25548) doi: 10.2196/25548
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Introduction
Background
Cardiovascular diseases are the leading cause of mortality
worldwide. In 2017, approximately 17.5 million people died
from cardiovascular diseases. Atherosclerotic cardiovascular
disease (ASCVD) was responsible for 7.3 million deaths in
2007, which increased to 8.93 million in 2017. During the same
period, mortality associated with cerebrovascular disease
increased from 5.29 to 6.17 million events. Moreover, 82% of
deaths in people ≤70 years occurred in low- and middle-income
countries [1].
In 2015, more than 100 million people worldwide were
diagnosed with ASCVD [2]. This population has been estimated
to have a four- to five-fold increased risk of a new
cardiovascular event in comparison with individuals without
ASCVD history [3].
Robust evidence indicates that the use of antiplatelet agents,
β-blocker agents, angiotensin-converting enzyme inhibitors
(ACEIs), and statins reduces the incidence of fatal and nonfatal
cardiovascular events in this population and is cost-effective.
These medications are recommended by all international
guidelines for the management of ASCVD [4,5].
However, long-term adherence to medication regimens continues
to be suboptimal, and many patients stop medication for various
reasons other than adverse side effects [6,7]. Only less than half
of the patients with known ASCVD in high-income countries
are receiving this group of cardiovascular medications, and the
situation is much worse in low- to middle-income countries
(LMICs), where only 1 in 20 patients with ASCVD received
all four types of cardiovascular drugs in 2011 [8].
The widespread use of mobile devices allows the
implementation of strategies such as text messaging to increase
medication adherence. It has shown some promising results
among patients with diabetes [9], HIV [10], and tuberculosis
[11] and may therefore help improve adherence for patients
with ASCVD [12,13]. In addition, access to the use of mobile
telephones globally has increased in recent years. For example,
in Colombia, telephone coverage increased from 84% in 2009
to 98.1% in 2019 [14].
A 2017 Cochrane review [15] evaluated the effects of SMS text
messaging on medication adherence in patients with ASCVD.
The review included 7 trials (n=1310) and reported the beneficial
effect of SMS text messaging on adherence to medications in
6 of these trials. However, the quality of the evidence was very
low. The Cochrane review identified the following limitations:
(1) trials had small sample sizes (n=34-521); (2) most trials had
a short follow-up period (<6 months); (3) the primary outcomes
reported were of limited clinical relevance; (4) most studies
recruited only patients with acute coronary syndrome and
excluded an important group of patients with other arterial
occlusive events (eg, stroke, peripheral vascular disease, and
programmed coronary revascularization) who should be
amenable for this type of intervention; (5) few studies were
performed in LMICs; and (6) most trials did not describe the
processes for SMS text messaging content generation, and the
few trials that did report these processes did not target the key
knowledge and attitudinal factors that are known to influence
adherence to medication; instead, the interventions were simple
reminders [15]. In summary, although there are some promising
small studies, there is a need to provide high-quality evidence
to assess the effect of SMS text messaging using behavior
change techniques to increase long-term medication adherence
in patients with ASCVD in LMICs.
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This study aims to fill this gap and provide evidence on whether
theory-based and context-specific SMS text messages increase
medication adherence for the secondary prevention of ASCVD
in Colombia. We developed an intervention (ie, SMS text
message) following the recommendations of Abroms et al [16]:
a review of the literature, conduct of qualitative studies, and
use of formal theories and behavior change techniques
(Transtheoretical Model of Behavior Change). Details of our
intervention development have been described previously
[17,18].
The main aim of this study is to evaluate the efficacy and safety
of an SMS text messaging intervention delivered by mobile
phones to improve adherence to cardiovascular medications in
patients with ASCVD. The intervention efficacy was assessed
by measuring blood serum low-density lipoprotein cholesterol
(LDL-C) levels as an indicator of adherence to statins, systolic
blood pressure (SBP) as an indicator of adherence to
blood-lowering therapies (ACEI or angiotensin II receptor
blockers [ARBs]), and heart rate (HR) as an indication of
adherence to β-blockers. The secondary objectives are to assess
the impact of SMS text messaging on self-reported adherence
to medications, hospitalizations, and the composite end point
of incident major adverse cardiovascular events at 12 months.
Methods
The full methodology of TXT2HEART Colombia has been
previously published [17] and is summarized here. We report
the following CONSORT (Consolidated Standards of Reporting
Trials) recommendations [19].
Study Design and Participants
In this two-arm parallel, single-blind individually randomized
controlled trial, adult patients aged ≥18 years with a history of
at least one of the following arterial occlusive events were
included: acute coronary syndrome (unstable angina or acute
myocardial infarction with or without ST elevation), stable
angina, ischemic cerebrovascular disease, peripheral arterial
disease, or coronary revascularization (coronary artery bypass
surgery or percutaneous transluminal coronary angioplasty).
Patients had to own a mobile phone and were able to read the
SMS text message. They were excluded if they had a known
contraindication to take all appropriate cardiovascular secondary
prevention medications. All patients were recruited from a single
center, the Fundación Cardiovascular de Colombia, a tertiary
hospital serving as a reference center for cardiovascular diseases
in Northeastern Colombia. The hospital has a clinical studies
office and has been certified in good clinical practice by national
and international authorities. All electronic health records were
scanned using SQL queries, identifying patients with at least
one month and without a maximum limit of time elapsed since
the last hospitalization for ASCVD. The records were then
manually inspected by 2 experienced medical doctors.
Qualifying patients were contacted by phone, and if they met
the inclusion criteria and were currently admitted or attended
the outpatient clinic with a diagnosis of ASCVD, they were
invited to participate. The process for evaluating potentially
eligible individuals is described in Multimedia Appendix 1.
Written informed consent was obtained from all subjects before
the study.
Intervention
The intervention consisted of behavior modification techniques
based on the Transtheoretical Model [16] to be delivered via
SMS text messaging. In our previous study [18], a protocol was
carried out to determine the content, quantity, and frequency of
SMS text messages through focus groups, validation of experts,
user feedback, and pretest. The messages included information
on the health implications of adherence to health habits (or lack
thereof) and indications and recommendations on how to take
their medication and promote healthy medication habits. They
provided or encouraged social support activities for correct
compliance with the prescribed treatment. The result of that
study was 86 SMS text messages (including 12 SMS text
messages of control and one welcome to the study), which were
the messages used as an intervention in this clinical trial and
the methodology of its delivery.
SMS text messages were sent through an automated text
messaging platform (Telerivet), which was fed directly with
data registered in Commcare, the platform for patient
registration. Volunteers were informed about the unidirectional
nature of the text messages and warned that no replies were
expected. If the patients replied the word “PARE” or “Detener”
(stop in Spanish), then no more messages were delivered. Text
messaging was started a day after patient randomization.
Messages were delivered every day for the first 4 weeks, and
then five messages were delivered in week 5. From week 6
onward, three messages were delivered per week; from week 8
until week 52, one message was delivered per week. Messages
were delivered on random weekdays from 8 AM to 6 PM to
prevent patients from predicting delivery times, in accordance
with a previous validation with study subjects. If the patient
withdrew from the study or died, we stopped sending the SMS
text messages. No tailoring considerations or modifications
were made during the trial.
Control Group
Patients in the control group only received SMS text messages
regarding the next study appointment, requesting information
about changes in their phone number, acknowledging them for
participating in the study, and reminding them of the importance
of the study. Messages were sent every month. These messages
were also sent to the intervention group and were generated
during SMS text message validation in the general population.
Examples of TXT2HEART Colombia SMS text messages are
included in Multimedia Appendix 2.
Outcomes
The primary outcome was a change in plasma LDL-C levels at
12 months. Blood samples were obtained at the start and end
of the study appointment. An improvement in LDL-C levels
was considered a surrogate indicator of adherence to statin
treatment. The secondary outcomes were SBP as an indicator
of adherence to blood-lowering therapies (ACEI or ARBs), HR
as an indicator of adherence to β-blockers,
11-dehydrothromboxaneB2 urine levels adjusted for creatinine
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as an indicator of adherence to antiplatelet therapy, self-reported
adherence to cardiovascular medications used in secondary
prevention as measured using the Medication Adherence Report
Scale-5 (MARS-5) questionnaire, and rates of cardiovascular
death or hospitalization due to cardiovascular disease and
noncardiovascular death or hospitalization due to
noncardiovascular disease. We also included road traffic crashes
(the only potential known hazard of SMS text messaging) and
death due to all causes as secondary outcomes.
The psychometric properties of the MARS-5 have been
previously reported [20]. The MARS-5 demonstrated acceptable
reliability (internal and test-retest) and validity (criterion-related
and construct validity). Internal reliability (Cronbach α) ranged
from .67 to .89 across all patient groups; the test-retest reliability
(Pearson r) was 0.97 for hypertension. Criterion-related validity
was established with more adherent patients with hypertension
showing better blood pressure control (χ21=4.2; P=.04).
Construct validity with beliefs about medicines was
demonstrated; higher adherence was associated with stronger
beliefs in treatment necessity and lower concerns about the
medication.
All study participants were seen twice upon admission to the
study for baseline assessment and randomization and at the end
of the follow-up period for a 12-month office visit. A follow-up
telephone call was made 3 months after randomization asking
about new hospital admissions, all-cause death, or cardiovascular
death, and adverse events were also recorded. SBP, resting HR,
and urinary levels of thromboxane B2 were recorded at the first
and final visits. Self-informed cardiovascular medication
prescription compliance was assessed using the MARS-5 at
both visits. The scale was applied by trained personnel,
considering automatic compliance if a total score of 25 was
achieved. Subjective medication intake compliance was assessed
on days 7 and 30. Data obtained about recurrent ASCVD were
requested on the phone interview or by physical examination;
oral reports by patients or relatives were allowed; and
cardiovascular or any cause mortality was recorded. Information
obtained on the phone was confirmed in all cases by reviewing
medical case notes, registries, or death certificates. Written
evidence for any event was requested via electronic mail,
WhatsApp messaging, or case note copies. If death or any major
event or hospital admission occurred during the follow-up
period, a hard copy of the death certificate from the patients’
relatives or case notes was requested on the 12-month follow-up
visit. At the final follow-up, all biomarkers were processed
simultaneously to avoid interference due to the reactive
processing, and the simple handling protocol depicted in the
protocol was followed [17]. At the initial appointment, we
recorded at least three different phone numbers and a complete
house address for each subject. A study identification card was
provided with a written record of the date of the last visit to the
trial, name of the principal investigator, and clinic contact phone
numbers. To ensure no loss of follow-up, any home-number
modifications were actively searched and recorded. The
appointment follow-up interval was kept to avoid any
interference with the study results.
Sample Size
The original sample size of the study was 1600 participants,
based on a 97% power to detect a 10% difference between arms
in adherence. In the published protocol [17] of this trial, a table
with power calculations under different assumptions was
included. However, due to limited study funding, the final
sample recruited was 930 participants, 805 (86.5%) of whom
reported LDL-C at the final visit. With 400 patients per arm
(based on an expected mean reduction of 80 mg/dl on plasma
levels of LDL-C in an adherence population and an expected
mean reduction of 16 mg/dl on a nonadherent population to
atorvastatin 20 mg) and assuming a 5% type I error, a power
>92% was estimated to detect a 10% difference in protocol
compliance between both intervention arms. A table with power
calculations for this sample size under different assumptions is
included in Multimedia Appendix 3.
Randomization
Block randomization was used, with block sizes of 5 patients
each in a 1:1 allocation ratio, and assignment was done
automatically using a remote computer-based randomization.
Once the patient met the inclusion and exclusion criteria and
signed the consent form, the data capture platform Commcare
(Dimagi) applied a logarithm of randomization assigning the
arm for the patient. This information was not shown to the
interviewer to maintain blindness, although he did confirm its
effective completion on the digital form. The data capture
platform accessed the services of the SMS text messaging
platform (Telerivet), categorizing the SMS text messaging group
to send according to the assigned group.
Blinding
Owing to the nature of the intervention, the participants could
not be blinded. However, all investigation personnel inputting
data were blinded to the individual’s group assignment, and all
patients were asked not to reveal their allocation details to the
study personnel. The study had an engineer who was the only
person who could access the messaging and database platforms.
He could access the data to sort patient queries or help solve
reception or technical issues. He was specifically trained on the
importance of maintaining blinding. Investigators handling and
analyzing the data were blinded to the intervention assigned.
Statistical Analysis
The distributions of the baseline characteristics were compared
between the intervention and control groups for all randomized
patients, those who completed the follow-up and those who did
not complete the follow-up, performing an intention to treat
analysis. Analysis of the continuous outcomes (ie, LDL-C,
thromboxane, HR, SBP, diastolic blood pressure [DBP], and
quantitative measures of adherence) was performed using linear
regression models. In each model, the dependent variable was
the difference between 12-month follow-up and the baseline of
the outcome, and the main explanatory variable was the
intervention group. Furthermore, the Patient Health
Questionnaire-9 (PHQ-9) scale (to measure depression) was
collected at baseline, as it was considered a potential
confounding factor for adherence to medication. All linear
regression models were adjusted by the baseline value of the
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outcome, centered on the mean. The effect of the intervention
was the difference between the arms in the expected change in
an individual and the average outcome value at baseline. Binary
outcomes (ie, hospitalization and mortality) were analyzed by
comparing the proportion of occurrence in both arms. No
adverse events were reported; therefore, we did not conduct any
analyses regarding this outcome. All P values were from
two-sided tests, and the data were analyzed using Stata version
14.0 (StataCorp). No interim analyses were performed.
Ethical Considerations
The Ethics Committee of the Fundación Cardiovascular de
Colombia evaluated and approved the trial (reference 375-2015).
The study was conducted in compliance with the protocol,
regulatory requirements, Good Clinical Practice, the Declaration
of Helsinki, and the clinical investigations guidelines of the
Fundación Cardiovascular de Colombia.
Data Availability
The data sets generated during this study are not publicly
available because availability was not included in the study plan
approved by the ethics committee but are available from the
corresponding author on reasonable request.
Results
Participant Flow
From April 18, 2017, to August 21, 2018, 930 patients were
randomized. A total of 49.7% (462/930) of patients were
assigned to the intervention arm and 50.3% (468/930) were
included in the control arm (Figure 1), of which 1.7% (16/930)
of patients replied “stop” to the messages (6 in intervention
group and 10 control), all of whom were followed up until the
end of the study. In total, 13.4% (125/930) losses to follow-up
occurred, 71 in the intervention group and 54 in the control
group.
A total of 86.8% (805/930) of participants completed the trial
follow-up at 12 months for the primary outcome (intervention
group: n=391; control: n=414; Figure 1). Retention did not differ
between two arms (71/462, 15.4% in the intervention group vs
54/468, 11.5% in the control group; P=.09). The main predictors
of retention were male sex (OR 1.61, 95% CI 1.05-2.46; P=.03)
and high total PHQ-9 score (OR 0.37, 95% CI 0.15-0.92; P=.03).
The effect of these predictors did not differ between the groups
(interaction test values: P=.23 and P=.80, respectively). The
characteristics of the participants who completed the follow-up
and those who did not are reported in Multimedia Appendix 4.
For secondary outcomes, HR, SBP, and DBP of 850 patients
were evaluated. For TxBA2, only 801 patients were evaluated
because 4 patients were unable to deliver the urine sample. In
addition, 807 patients were assessed using the MARS-5. New
cardiovascular events were evaluated in 910 patients and
mortality was evaluated in 919 patients through telephone
interviews.
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Figure 1. CONSORT (Consolidated Standards of Reporting Trials) diagram.
Baseline Characteristics
The baseline characteristics of the participants (N=930), which
were similar between the two groups, are summarized in Table
1. Overall, most participants (729/930, 78.4%) were men, and
the mean age was 63.5 years (SD 9.8); 88.9% (827/930) were
using statins, 94.52% (879/930) were on antiplatelet aggregation
therapy, and β-blocker use was reported in 83.2% (774/930) of
participants, whereas ACEI or ARBs use was observed in 68.1%
(633/930) of participants. The average MARS-5 score at baseline
was 22.8, and 41.72% (388/930) of participants considered
adherent (MARS-5 score=25). Clinical and laboratory
characteristics such as PHQ-9, BMI, LDL-C, SBP, DBP, HR,
and thromboxane B2 were similar between the two groups
(Table 1). The baseline characteristics of participants with
primary outcome completers and primary outcome
noncompleters are shown in Multimedia Appendix 4, and the
MARS-5 scores at baseline are shown in Figure 2.
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Table 1. Characteristics of study participants at baseline (N=930).
Participants
(N=930)
Intervention group (n=462)Control group (n=468)Characteristics
63.5 (9.8)64.0 (9.7)63.1 (10)Age (years), mean (SD)
Gender, n (%)
201 (21.6)109 (23.6)92 (19.7)Female
729 (78.4)353 (76.4)376 (80.3)Male
Time since the last event, n (%)
105 (11.3)43 (9.3)62 (13.3)Less than 3 months
181 (19.5)97 (21)84 (17.9)3 to 12 months
266 (28.6)122 (26.4)144 (30.8)1 to 3 years
378 (40.7)200 (43.3)178 (38)More than 3 years
Type event, n (%)
663 (71.3)327 (70.8)336 (71.8)Acute coronary syndrome
56 (6)23 (5)33 (7.1)Stable angina
42 (4.5)21 (4.6)21 (4.5)Ischemic cerebrovascular disease
36 (3.9)21 (4.6)15 (3.2)Peripheral arterial disease
133 (14.3)70 (15.2)63 (13.5)Coronary revascularization
Prescribed medications, n (%)
827 (88.9)413 (89.4)414 (88.5)Statins
633 (68.1)306 (66.2)327 (69.9)ACEIa or ARBsb
774 (83.2)392 (84.9)382 (81.6)β-blocker
879 (94.5)437 (94.6)442 (94.4)Platelet aggregation inhibitors
22.9 (3.6)23 (3.31)22.8 (3.78)MARS-5c score, mean (SD)
388 (41.7)189 (40.9)199 (42.5)Adherent (MARS-5 score=25 points), n (%)
Self-reported adherence, mean (SD)
9.1 (2.1)9.1 (2.19)9.1 (2.04)Last 7 days (0-10 scale)
9.1 (2)9.1 (2.05)9.1 (1.95)30 days (0-10 scale)
PHQ-9d, n (%)
666 (71.6)323 (69.9)343 (73.3)Minimal depression (<5)
239 (25.7)127 (27.5)112 (24)Moderate depression (5-14)
25 (2.7)13 (2.8)12 (2.6)Moderately severe depression or severe (>14)
Smoking, n (%)
28 (3)12 (2.6)16 (3.4)Smoker
353 (38)185 (40)168 (35.9)Never smoked
549 (59)265 (57.4)284 (60.7)Past smoker
27.6 (4.2)27.3 (4.2)27.9 (4.2)BMI (m/kg2), mean (SD)
88.4 (37.7)88.5 (38.0)88.2 (37.4)LDLe (mg/dl), mean (SD)
129.0 (20.9)129.9 (20.9)128.2 (20.8)SBPf (mmHg), mean (SD)
71.7 (11.5)71.9 (11.3)71.5 (11.7)DBPg (mmHg), mean (SD)
68.8 (11.1)68.8 (10.6)68.9 (11.7)Heart rate (bpm), mean (SD)
64.2 (157.6)64.2 (167.7)64.1 (147.2)Thromboxane B2h (ng/ml), mean (SD)
aACEI: angiotensin-converting enzyme inhibitor.
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bARB: angiotensin II receptor blocker.
cMARS-5: Medication Adherence Report Scale-5.
dPHQ-9: Patient Health Questionnaire-9.
eLDL: low-density lipoprotein.
fSBP: systolic blood pressure.
gDBP: diastolic blood pressure.
hCreatinine adjusted (mg/dl).
Figure 2. Distribution of the MARS-5 scores at baseline. Graphs by Intervention. MARS-5: Medication Adherence Report Scale-5.
Outcomes
We did not find evidence (P=.41) that the intervention was
more effective than the control according to changing plasma
LDL-C levels (adjusted by baseline value) at 12 months. We
also did not find significant differences between the two groups
in terms of secondary outcomes analyzed including thromboxane
B2 levels, HR, SBP, DBP, adherence measured by MARS-5,
or clinical events (hospitalization or death) at one year of
follow-up (Table 2).
There were no adverse events related to this study. In total, three
falls that required hospitalization were reported; in all of them,
medical evaluation and patient interviews were performed,
eliminating any relationship between mobile phone use and fall
events. No traffic accidents occurred.
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Table 2. Summary of primary and secondary outcomesa.





















Primary outcome, mean (SD)










Thromboxane B2 (ng/ml)e, mean
(SD)
.48N/AN/A0.54 (−1.0 to 2.1)0.6 (10.5)−0.1 (13.9)68.5 (10.5)68.6
(11.6)
Heart rate (bpm), mean (SD)




SBPf (mmHg), mean (SD)
.30N/AN/A−0.70 (−2.0 to 0.6)−0.1 (10.7)0.7 (11.7)71.7 (11.3)71.5
(11.9)
DBPg (mmHg), mean (SD)
.96N/AN/A−0.01 (−0.4 to 0.4)−0.02 (3.4)0.2 (3.7)23.1 (3.1)22.8
(3. 8)
MARS-5h (score), mean (SD)
.69N/AN/A0.05 (−0.2 to 0.3)0.2 (2.0)0.1 (2.0)9.2 (2.0)9.1
(2.1)
Self-reported adherence (7 days),
mean (SD)











N/AN/A27 (5.8)32 (6.8)N/AN/AHospitalization for cardiovascu-














N/AN/A14 (3)8 (1.7)N/AN/ADeath from any causej, n (%)
aSample sizes may vary slightly because some individuals have missing values.




fSBP: systolic blood pressure.
gDBP: diastolic blood pressure.
hMARS-5: Medication Adherence Report Scale-5.
iWithin each group is the number of patients that lose adherence over those that became adherent.
jWithin each group is the proportion of patients who experienced the event.
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In this study, a behavioral modification intervention delivered
by SMS text messages did not decrease LDL-C level, the
primary outcome, and did not find evidence of an impact on
any of the other biological markers assessed, including blood
pressure, HR, or thromboxane; clinical events; or medication
adherence, as measured by the MARS-5 or self-reporting.
This study has many strengths. First, a thorough and detailed
formative research was followed to develop a tailored behavioral
modification intervention, which has been previously published
[17] alongside the study protocol. Different outcomes have been
collected, including self-reporting of adherence, validated
adherence tools (ie, the MARS-5 has demonstrated acceptable
reliability [internal and test-retest] and validity [criterion-related
and construct validity]) [20], and proxy biological markers, and
they were triangulated to evaluate adherence. A rigorous plan
was put in place to ensure that the intervention was delivered
appropriately, study investigators collecting data were blinded
to the patient allocation arm, and most patients were followed
up for the primary and secondary outcomes at 12 months.
Finally, even if the sample size was smaller than originally
planned, to the best of our knowledge, this study is the largest
to date to assess the effect of a behavioral modification
intervention delivered by SMS text messages to increase
adherence in people with ASCVD.
Limitations
This study also presented some limitations; although sending
text messages could be confirmed, neither the correct reading
of the message nor the stage of the transtheoretical behavioral
modification reached by each participant was evaluated [18].
In addition, the inability to blind patients would have increased
the likelihood of underreporting nonadherence. This is a
common problem with self-reports when patients may
exaggerate their adherence if they believe that reports of
nonadherence will disappoint their health provider
(self-presentational bias) [21]. The MARS-5 addresses this
problem by taking steps to diminish self-presentational bias.
Introductory statements normalize nonadherence, conveying a
no-blame approach [8]. As another step to minimize
self-presentational bias, patients were told that their responses
to the study questionnaires would not be seen by the health care
professionals providing care. In addition, we conducted a case
analysis on all lost cases, assuming that all related losses were
random, but due to the low rate of loss to follow-up and that its
main predictors (sex and PHQ-9) were similar in both arms of
the study, we do not consider that these losses had a major
impact on the results of the trial.
Another limitation was that SMS text messages were not
customized according to the patient categories. However, as
mentioned earlier, this formative research was detailed, and a
formal theory was applied to develop the content of the
messages. Unfortunately, due to the lack of funding, we could
not conduct a comprehensive mixed methods process evaluation
to shed light on some of the mechanisms and contexts that could
explain the effect on specific subgroups of patients. Finally,
measuring adherence is always challenging; a validated scale
(ie, MARS-5) was used and self-reporting measures were used,
but pill count was not taken into consideration; however, the
direct measurement of adherence was complemented with
indirect measurements, such as those for LDL-C, blood pressure,
HR, and thromboxane.
A previous Cochrane review [15] published in 2017 identified
studies reporting positive effects; however, all studies had small
sample sizes and high risk of bias and therefore provided a low
level of evidence. The TEXT ME study was a randomized
controlled trial that included 710 patients with coronary artery
disease who did not report medication adherence but did report
that four text messages sent per week led to reductions in LDL-C
levels and blood pressure at 6 months [22]; however, a more
recent multi-center randomized controlled trial in China
including 822 patients with coronary artery disease reported
that SMS text messages did not reduce blood pressure or LDL-C
levels at 6 months [23].
The lack of evidence of a beneficial effect reported by the
intervention could be due to different reasons; the study might
have lacked the power to detect an effect as the sample size was
lower than intended; however, with 930 patients, it was well
powered to detect a reasonable, modest, clinical benefit. The
lack of benefit could be potentially explained by the fact that
the baseline levels of medication adherence were already quite
high, with a mean MARS-5 of 9.1 out of 10 at 7 and 30 days;
therefore, there was little room for improvement. Another
possible explanation could be related to intervention content.
Although the intervention went beyond simple prompts and
reminders (a thorough process was followed with the objective
of changing beliefs and motivations), it was not tailored enough
to change beliefs and motivations in the study context, or
perhaps in this highly adherent population, these issues were
not the main drivers of nonadherence. The findings could also
be related to issues related to the delivery of the SMS text
messages (ie, timing, frequency, and length of intervention),
due to the effects of fatigue, overload, or loss of interest in SMS
text messages. SMS text messaging interventions have been
shown to be effective in modifying lifestyle issues (eg, tobacco
cessation) where the goals of the patient and the intervention
are closely aligned; however, they might be less effective on
adherence [24]. Another possible explanation is that the results
were measured at 12 months, and it has been shown that
adherence interventions are more effective in the short term (3
to 6 months) [25]. Planning only one intermediate measure at
3 months to assess the presence of rehospitalizations or death
may limit the comparison of this study with others, but the
protocol prioritized the pragmatic conditions of the trial,
avoiding face-to-face contacts (eg, adherence questions), because
this would represent an additional study activity to the real
scenario of the patients, leading to a potential Hawthorne effect
that can alter the results of the effectiveness of SMS text
messages. Another explanation for the difference found in the
studies included in the Cochrane review could be related to the
fact that only a third of the patients recruited in our study had
an index event within the last year.
Finally, having data from a single site is a limitation in
generalizing our results to different scenarios; however, it is
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important to note that the institution where the study was
conducted is a reference center in Northeastern Colombia, and
its area of influence included a population of 5 million.
Conclusions
This study did not find evidence that a behavior modification
intervention delivered by SMS text messaging improves
medication adherence, LDL-C, or blood pressure levels at 12
months. Although its potential use to increase medication
adherence in patients with ASCVD remains as a potentially
attractive and scalable solution to a very important problem,
further research is needed. Future research should include
interventions, including SMS text messages blended with other
components, tailored to the specific issues and beliefs of
individual participants. Implementation studies using mixed
methods and innovative approaches that evaluate how different
intervention characteristics (behavioral modification
component), SMS text message delivery strategies (eg, timing
of initiation, frequency, duration, and personalization), and
context (eg, type of patients, health system, and social
environment) influence the effect of this intervention should be
conducted.
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